TACN-based cationic lipids with amino acid backbone and double tails: Materials for non-viral gene delivery

2014 ◽  
Vol 24 (7) ◽  
pp. 1771-1775 ◽  
Author(s):  
Bing Wang ◽  
Wen-Jing Yi ◽  
Ji Zhang ◽  
Qin-Fang Zhang ◽  
Miao-Miao Xun ◽  
...  
Keyword(s):  
Amino Acid ◽  
Gene Delivery ◽  
Cationic Lipids ◽  
Viral Gene ◽  
Viral Gene Delivery

scholarly journals Cationic lipids with a cyclen headgroup: synthesis and structure–activity relationship studies as non-viral gene vectors

RSC Advances ◽  
2017 ◽  
Vol 7 (30) ◽  
pp. 18681-18689 ◽  
Author(s):  
De-Chun Chang ◽  
Yi-Mei Zhang ◽  
Ji Zhang ◽  
Yan-Hong Liu ◽  
Xiao-Qi Yu
Keyword(s):  
Gene Delivery ◽  
Structure Activity Relationship ◽  
Cationic Lipids ◽  
Activity Relationship ◽  
Viral Gene ◽  
Structure Activity Relationships ◽  
Structure Activity ◽  
Gene Delivery Vectors ◽  
Gene Vectors ◽  
Viral Gene Delivery

The structure–activity relationships of cyclen-based cationic lipids as non-viral gene delivery vectors were studied and clarified.

Cholesterol derived cationic lipids as potential non-viral gene delivery vectors and their serum compatibility

2016 ◽  
Vol 26 (10) ◽  
pp. 2401-2407 ◽  
Author(s):  
Jia Ju ◽  
Meng-Lei Huan ◽  
Ning Wan ◽  
Yi-Lin Hou ◽  
Xi-Xi Ma ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Cationic Lipids ◽  
Viral Gene ◽  
Gene Delivery Vectors ◽  
Viral Gene Delivery

Biotinylated Cyclen-Contained Cationic Lipids as Non-Viral Gene Delivery Vectors

2013 ◽  
Vol 82 (4) ◽  
pp. 376-383 ◽  
Author(s):  
Qiang Liu ◽  
Wen-Jing Yi ◽  
Yi-Mei Zhang ◽  
Ji Zhang ◽  
Liandi Guo ◽  
...  
Keyword(s):  
Gene Delivery ◽  
Cationic Lipids ◽  
Viral Gene ◽  
Gene Delivery Vectors ◽  
Viral Gene Delivery

Introduction of cyclic guanidines into cationic lipids for non-viral gene delivery

2000 ◽  
Vol 41 (5) ◽  
pp. 675-679 ◽  
Author(s):  
Marc Frederic ◽  
Daniel Scherman ◽  
Gerardo Byk
Keyword(s):  
Gene Delivery ◽  
Cationic Lipids ◽  
Viral Gene ◽  
Viral Gene Delivery

scholarly journals Amino Acid-Linked Low Molecular Weight Polyethylenimine for Improved Gene Delivery and Biocompatibility

Molecules ◽  
2020 ◽  
Vol 25 (4) ◽  
pp. 975 ◽  
Author(s):  
Xiao-Ru Wu ◽  
Ji Zhang ◽  
Ju-Hui Zhang ◽  
Ya-Ping Xiao ◽  
Xi He ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Amino Acid ◽  
Gene Delivery ◽  
Transfection Efficiency ◽  
Gel Permeation Chromatography ◽  
Viral Gene ◽  
Low Molecular Weight ◽  
Ph Buffering ◽  
Gene Delivery Vectors ◽  
Viral Gene Delivery

The construction of efficient and low toxic non-viral gene delivery vectors is of great significance for gene therapy. Herein, two novel polycations were constructed via Michael addition from low molecular weight polyethylenimine (PEI) 600 Da and amino acid-containing linkages. Lysine and histidine were introduced for the purpose of improved DNA binding and pH buffering capacity, respectively. The ester bonds afforded the polymer biodegradability, which was confirmed by the gel permeation chromatography (GPC) measurement. The polymers could well condense DNA into nanoparticles and protect DNA from degradation by nuclease. Compared with PEI 25 kDa, these polymers showed higher transfection efficiency, lower toxicity, and better serum tolerance. Study of this mechanism revealed that the polyplexes enter the cells mainly through caveolae-mediated endocytosis pathway; this, together with their biodegradability, facilitates the internalization of polyplexes and the release of DNA. The results reveal that the amino acid-linked low molecular weight PEI polymers could serve as promising candidates for non-viral gene delivery.

Recent advances in the analysis full/empty capsid ratio and genome integrity of adeno-associated virus (AAV) gene delivery vectors

2020 ◽  
Vol 20 ◽  
Author(s):  
L. Hajba ◽  
A. Guttman
Keyword(s):  
Gene Delivery ◽  
High Efficiency ◽  
Analytical Techniques ◽  
Viral Gene ◽  
Adeno Associated Virus ◽  
Gene Delivery Vectors ◽  
Empty Capsid ◽  
Purification Methods ◽  
Viral Gene Delivery

: Adeno-associated virus (AAV) is one of the most promising viral gene delivery vectors with long-term gene expression and disease correction featuring high efficiency and excellent safety in human clinical trials. During the production of AAV vectors,there are several quality control (QC)parameters that should be rigorously monitored to comply with clini-cal safety and efficacy. This review gives a short summary of the most frequently used AVV production and purification methods,focusing on the analytical techniques applied to determine the full/empty capsid ratio and the integrity of the encapsidated therapeutic DNA of the products.

Sign in / Sign up

Export Citation Format

Share Document